Sickle cell anemia

Hello!  We're happy that you've chosen to use HemOnc.org, and hope that you will return often. From now until January 31, we are conducting a survey to learn more about our users and how we can make the site better and more useful.  Please help us by filling it out!  Link: http://j.mp/2BlBaoQ

Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer. If this is your first time visiting, we suggest you read the tutorial.

Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.

Section editors
	Shruti Chaturvedi, MD, MSCI Baltimore, MD LinkedIn		Benjamin Tillman, MD Nashville, TN

6 regimens on this page 6 variants on this page

Guidelines

NHLBI

• 2014: Evidence-Based Management of Sickle Cell Disease: Expert Panel Report, 2014

All lines of therapy

Hydroxyurea monotherapy

back to top

Regimen

Study	Evidence	Comparator	Efficacy
Charache et al. 1995 (MSH)	Phase III	Placebo	Superior annual rate of crises

Chemotherapy

• Hydroxyurea (Hydrea) 15 mg/kg/day PO

Doses were subsequently adjusted, see article for details.

References

1. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, McMahon RP, Bonds DR. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med. 1995 May 18;332(20):1317-22. link to original article contains protocol PubMed
   1. Update: Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, Orringer E, Bellevue R, Olivieri N, Eckman J, Varma M, Ramirez G, Adler B, Smith W, Carlos T, Ataga K, DeCastro L, Bigelow C, Saunthararajah Y, Telfer M, Vichinsky E, Claster S, Shurin S, Bridges K, Waclawiw M, Bonds D, Terrin M. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 2003 Apr 2;289(13):1645-51. Erratum in: JAMA. 2003 Aug 13;290(6):756. link to original article PubMed
2. QoL analysis: Ballas SK, Barton FB, Waclawiw MA, Swerdlow P, Eckman JR, Pegelow CH, Koshy M, Barton BA, Bonds DR. Hydroxyurea and sickle cell anemia: effect on quality of life. Health Qual Life Outcomes. 2006 Aug 31;4:59. link to original article link to PMC article PubMed

L-glutamine monotherapy

back to top

Regimen

Study	Evidence	Comparator	Efficacy
No publication	Phase III	Placebo	Superior reduction in the number of sickle cell crises through week 48

Note: this trial is not available in published form; instructions here are from the ClinicalTrials.gov page.

Therapy

• L-glutamine (Endari) 0.3 g/kg PO BID

48-week course

References

1. ClinicalTrials.gov